MEDIANTECHNOLOGIES news, videos and press releases
For more news please use our advanced search feature.
MEDIANTECHNOLOGIES - More news...
MEDIANTECHNOLOGIES - More news...
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
- Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 17, 2025
- Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
- Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
- Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
- Median Technologies to Participate in Several Investor Conferences in May and June 2025
- Median Technologies Reports Full-year 2024 Financial Results
- Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025
- eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025
- Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025
- Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
- Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025
- Median Technologies Gives Update on Drawdowns of the Iris Equity Line
- Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
- Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
- Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU
- Median Technologies: Financial Communications Schedule for the First Half of 2025
- Half Year Median Technologies Liquidity Contract Statement
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024
- Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024
- Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31st, 2023
- Median Technologies: Financial Communication Schedule for the Second Half of 2023
- Portzamparc Groupe BNP Paribas Initiates the Coverage of Median Technologies with a “Strong Buy” Recommendation
